nodes	percent_of_prediction	percent_of_DWPC	metapath
Orphenadrine—SCN10A—skin cancer	0.774	1	CbGaD
Orphenadrine—CYP2E1—Dacarbazine—skin cancer	0.0488	0.288	CbGbCtD
Orphenadrine—CYP3A4—Temozolomide—skin cancer	0.0352	0.208	CbGbCtD
Orphenadrine—CYP3A4—Imiquimod—skin cancer	0.0352	0.208	CbGbCtD
Orphenadrine—CYP3A4—Vismodegib—skin cancer	0.0244	0.144	CbGbCtD
Orphenadrine—CYP3A4—Vemurafenib—skin cancer	0.0193	0.114	CbGbCtD
Orphenadrine—CYP3A4—Docetaxel—skin cancer	0.00662	0.0391	CbGbCtD
Orphenadrine—HRH1—nose—skin cancer	0.00177	0.165	CbGeAlD
Orphenadrine—SCN9A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00154	0.0816	CbGpPWpGaD
Orphenadrine—SCN4A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00141	0.075	CbGpPWpGaD
Orphenadrine—SCN1A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.00136	0.0724	CbGpPWpGaD
Orphenadrine—SCN10A—nerve—skin cancer	0.00113	0.105	CbGeAlD
Orphenadrine—SCN5A—Interaction between L1 and Ankyrins—SCN10A—skin cancer	0.000958	0.0509	CbGpPWpGaD
Orphenadrine—Skin disorder—Vismodegib—skin cancer	0.000828	0.0306	CcSEcCtD
Orphenadrine—Aplastic anaemia—Dactinomycin—skin cancer	0.000783	0.029	CcSEcCtD
Orphenadrine—Constipation—Vismodegib—skin cancer	0.000729	0.027	CcSEcCtD
Orphenadrine—Aplastic anaemia—Temozolomide—skin cancer	0.000708	0.0262	CcSEcCtD
Orphenadrine—SLC6A2—nerve—skin cancer	0.000706	0.0656	CbGeAlD
Orphenadrine—Asthenia—Vismodegib—skin cancer	0.000612	0.0226	CcSEcCtD
Orphenadrine—Pruritus—Vismodegib—skin cancer	0.000603	0.0223	CcSEcCtD
Orphenadrine—SCN9A—L1CAM interactions—SCN10A—skin cancer	0.00059	0.0313	CbGpPWpGaD
Orphenadrine—SCN4A—L1CAM interactions—SCN10A—skin cancer	0.000542	0.0288	CbGpPWpGaD
Orphenadrine—Vomiting—Vismodegib—skin cancer	0.000542	0.0201	CcSEcCtD
Orphenadrine—Anaphylactic shock—Vemurafenib—skin cancer	0.000527	0.0195	CcSEcCtD
Orphenadrine—SCN1A—L1CAM interactions—SCN10A—skin cancer	0.000523	0.0278	CbGpPWpGaD
Orphenadrine—Skin disorder—Vemurafenib—skin cancer	0.000512	0.0189	CcSEcCtD
Orphenadrine—GRIN2D—head—skin cancer	0.000507	0.047	CbGeAlD
Orphenadrine—Nausea—Vismodegib—skin cancer	0.000506	0.0187	CcSEcCtD
Orphenadrine—Agitation—Imiquimod—skin cancer	0.000506	0.0187	CcSEcCtD
Orphenadrine—Palpitations—Imiquimod—skin cancer	0.000486	0.018	CcSEcCtD
Orphenadrine—GRIN1—EPHB-mediated forward signaling—RASA1—skin cancer	0.000485	0.0258	CbGpPWpGaD
Orphenadrine—GRIN3A—head—skin cancer	0.000476	0.0442	CbGeAlD
Orphenadrine—GRIN1—head—skin cancer	0.000451	0.0419	CbGeAlD
Orphenadrine—Constipation—Vemurafenib—skin cancer	0.00045	0.0167	CcSEcCtD
Orphenadrine—Tachycardia—Imiquimod—skin cancer	0.000438	0.0162	CcSEcCtD
Orphenadrine—Skin disorder—Imiquimod—skin cancer	0.000436	0.0161	CcSEcCtD
Orphenadrine—Somnolence—Imiquimod—skin cancer	0.000399	0.0148	CcSEcCtD
Orphenadrine—Hypersensitivity—Vemurafenib—skin cancer	0.000388	0.0144	CcSEcCtD
Orphenadrine—GRIN2D—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.000388	0.0206	CbGpPWpGaD
Orphenadrine—Asthenia—Vemurafenib—skin cancer	0.000378	0.014	CcSEcCtD
Orphenadrine—Hallucination—Temozolomide—skin cancer	0.000377	0.0139	CcSEcCtD
Orphenadrine—Pruritus—Vemurafenib—skin cancer	0.000373	0.0138	CcSEcCtD
Orphenadrine—Feeling abnormal—Imiquimod—skin cancer	0.00037	0.0137	CcSEcCtD
Orphenadrine—SCN5A—L1CAM interactions—SCN10A—skin cancer	0.000368	0.0195	CbGpPWpGaD
Orphenadrine—KCNH2—nipple—skin cancer	0.00036	0.0334	CbGeAlD
Orphenadrine—Urticaria—Imiquimod—skin cancer	0.000357	0.0132	CcSEcCtD
Orphenadrine—Dizziness—Vemurafenib—skin cancer	0.000348	0.0129	CcSEcCtD
Orphenadrine—Vomiting—Vemurafenib—skin cancer	0.000335	0.0124	CcSEcCtD
Orphenadrine—SCN10A—lymphoid tissue—skin cancer	0.000334	0.031	CbGeAlD
Orphenadrine—Hypersensitivity—Imiquimod—skin cancer	0.000331	0.0122	CcSEcCtD
Orphenadrine—Headache—Vemurafenib—skin cancer	0.00033	0.0122	CcSEcCtD
Orphenadrine—Asthenia—Imiquimod—skin cancer	0.000322	0.0119	CcSEcCtD
Orphenadrine—Confusional state—Bleomycin—skin cancer	0.000322	0.0119	CcSEcCtD
Orphenadrine—GRIN2D—Post NMDA receptor activation events—BRAF—skin cancer	0.000319	0.0169	CbGpPWpGaD
Orphenadrine—Anaphylactic shock—Bleomycin—skin cancer	0.000319	0.0118	CcSEcCtD
Orphenadrine—Pruritus—Imiquimod—skin cancer	0.000318	0.0118	CcSEcCtD
Orphenadrine—SCN4A—head—skin cancer	0.000315	0.0293	CbGeAlD
Orphenadrine—Nausea—Vemurafenib—skin cancer	0.000313	0.0116	CcSEcCtD
Orphenadrine—Vision blurred—Temozolomide—skin cancer	0.000311	0.0115	CcSEcCtD
Orphenadrine—Tremor—Temozolomide—skin cancer	0.000309	0.0114	CcSEcCtD
Orphenadrine—GRIN1—Spinal Cord Injury—CSPG4—skin cancer	0.000308	0.0164	CbGpPWpGaD
Orphenadrine—SCN1A—head—skin cancer	0.000304	0.0282	CbGeAlD
Orphenadrine—Agitation—Temozolomide—skin cancer	0.000303	0.0112	CcSEcCtD
Orphenadrine—Dizziness—Imiquimod—skin cancer	0.000297	0.011	CcSEcCtD
Orphenadrine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000294	0.0156	CbGpPWpGaD
Orphenadrine—Palpitations—Temozolomide—skin cancer	0.000291	0.0108	CcSEcCtD
Orphenadrine—HRH1—nipple—skin cancer	0.000289	0.0268	CbGeAlD
Orphenadrine—Vision blurred—Fluorouracil—skin cancer	0.000286	0.0106	CcSEcCtD
Orphenadrine—Vomiting—Imiquimod—skin cancer	0.000286	0.0106	CcSEcCtD
Orphenadrine—Headache—Imiquimod—skin cancer	0.000281	0.0104	CcSEcCtD
Orphenadrine—GRIN1—CREB phosphorylation through the activation of Ras—BRAF—skin cancer	0.000278	0.0148	CbGpPWpGaD
Orphenadrine—Confusional state—Temozolomide—skin cancer	0.000271	0.01	CcSEcCtD
Orphenadrine—SCN10A—head—skin cancer	0.000269	0.025	CbGeAlD
Orphenadrine—Anaphylactic shock—Temozolomide—skin cancer	0.000269	0.00996	CcSEcCtD
Orphenadrine—Nausea—Imiquimod—skin cancer	0.000267	0.00987	CcSEcCtD
Orphenadrine—Feeling abnormal—Bleomycin—skin cancer	0.000263	0.00973	CcSEcCtD
Orphenadrine—Skin disorder—Temozolomide—skin cancer	0.000261	0.00967	CcSEcCtD
Orphenadrine—Urticaria—Bleomycin—skin cancer	0.000254	0.00938	CcSEcCtD
Orphenadrine—GRIN2D—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.00025	0.0133	CbGpPWpGaD
Orphenadrine—Confusional state—Fluorouracil—skin cancer	0.00025	0.00925	CcSEcCtD
Orphenadrine—GRIN1—EPH-Ephrin signaling—RASA1—skin cancer	0.00025	0.0133	CbGpPWpGaD
Orphenadrine—Anaphylactic shock—Fluorouracil—skin cancer	0.000248	0.00917	CcSEcCtD
Orphenadrine—SCN9A—lymph node—skin cancer	0.000248	0.023	CbGeAlD
Orphenadrine—Feeling abnormal—Dactinomycin—skin cancer	0.000245	0.00907	CcSEcCtD
Orphenadrine—SCN5A—head—skin cancer	0.000245	0.0227	CbGeAlD
Orphenadrine—Tachycardia—Fluorouracil—skin cancer	0.000242	0.00895	CcSEcCtD
Orphenadrine—Somnolence—Temozolomide—skin cancer	0.000239	0.00885	CcSEcCtD
Orphenadrine—Hypersensitivity—Bleomycin—skin cancer	0.000235	0.0087	CcSEcCtD
Orphenadrine—Constipation—Temozolomide—skin cancer	0.00023	0.00851	CcSEcCtD
Orphenadrine—Asthenia—Bleomycin—skin cancer	0.000229	0.00847	CcSEcCtD
Orphenadrine—GRIN1—Post NMDA receptor activation events—BRAF—skin cancer	0.000229	0.0121	CbGpPWpGaD
Orphenadrine—Pruritus—Bleomycin—skin cancer	0.000226	0.00835	CcSEcCtD
Orphenadrine—SCN9A—Axon guidance—SCN10A—skin cancer	0.000223	0.0118	CbGpPWpGaD
Orphenadrine—Feeling abnormal—Temozolomide—skin cancer	0.000222	0.00821	CcSEcCtD
Orphenadrine—Somnolence—Fluorouracil—skin cancer	0.00022	0.00816	CcSEcCtD
Orphenadrine—Hypersensitivity—Dactinomycin—skin cancer	0.000219	0.00811	CcSEcCtD
Orphenadrine—Urticaria—Temozolomide—skin cancer	0.000214	0.00791	CcSEcCtD
Orphenadrine—Asthenia—Dactinomycin—skin cancer	0.000214	0.0079	CcSEcCtD
Orphenadrine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—skin cancer	0.000211	0.0112	CbGpPWpGaD
Orphenadrine—CHRM2—head—skin cancer	0.000208	0.0193	CbGeAlD
Orphenadrine—SCN4A—Axon guidance—SCN10A—skin cancer	0.000205	0.0109	CbGpPWpGaD
Orphenadrine—HRH1—connective tissue—skin cancer	0.000205	0.019	CbGeAlD
Orphenadrine—Feeling abnormal—Fluorouracil—skin cancer	0.000204	0.00756	CcSEcCtD
Orphenadrine—Vomiting—Bleomycin—skin cancer	0.000203	0.00751	CcSEcCtD
Orphenadrine—SLC6A2—female reproductive system—skin cancer	0.000201	0.0186	CbGeAlD
Orphenadrine—Hypersensitivity—Temozolomide—skin cancer	0.000198	0.00734	CcSEcCtD
Orphenadrine—SCN1A—Axon guidance—SCN10A—skin cancer	0.000198	0.0105	CbGpPWpGaD
Orphenadrine—Urticaria—Fluorouracil—skin cancer	0.000197	0.00729	CcSEcCtD
Orphenadrine—HRH1—epithelium—skin cancer	0.000194	0.018	CbGeAlD
Orphenadrine—Palpitations—Docetaxel—skin cancer	0.000194	0.00717	CcSEcCtD
Orphenadrine—Asthenia—Temozolomide—skin cancer	0.000193	0.00714	CcSEcCtD
Orphenadrine—Pruritus—Temozolomide—skin cancer	0.00019	0.00704	CcSEcCtD
Orphenadrine—Nausea—Bleomycin—skin cancer	0.00019	0.00701	CcSEcCtD
Orphenadrine—CYP2B6—skin of body—skin cancer	0.000189	0.0176	CbGeAlD
Orphenadrine—Vomiting—Dactinomycin—skin cancer	0.000189	0.007	CcSEcCtD
Orphenadrine—SCN10A—lymph node—skin cancer	0.000189	0.0175	CbGeAlD
Orphenadrine—Hypersensitivity—Fluorouracil—skin cancer	0.000183	0.00676	CcSEcCtD
Orphenadrine—Confusional state—Docetaxel—skin cancer	0.000181	0.00668	CcSEcCtD
Orphenadrine—KCNH2—female reproductive system—skin cancer	0.00018	0.0167	CbGeAlD
Orphenadrine—GRIN1—Ras activation uopn Ca2+ infux through NMDA receptor—HRAS—skin cancer	0.000179	0.00951	CbGpPWpGaD
Orphenadrine—Anaphylactic shock—Docetaxel—skin cancer	0.000179	0.00662	CcSEcCtD
Orphenadrine—GRIN2D—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000178	0.00947	CbGpPWpGaD
Orphenadrine—Dizziness—Temozolomide—skin cancer	0.000178	0.00658	CcSEcCtD
Orphenadrine—Nausea—Dactinomycin—skin cancer	0.000177	0.00654	CcSEcCtD
Orphenadrine—Pruritus—Fluorouracil—skin cancer	0.000175	0.00649	CcSEcCtD
Orphenadrine—Tachycardia—Docetaxel—skin cancer	0.000175	0.00646	CcSEcCtD
Orphenadrine—Skin disorder—Docetaxel—skin cancer	0.000174	0.00643	CcSEcCtD
Orphenadrine—Vomiting—Temozolomide—skin cancer	0.000171	0.00633	CcSEcCtD
Orphenadrine—Headache—Temozolomide—skin cancer	0.000169	0.00624	CcSEcCtD
Orphenadrine—HRH1—mammalian vulva—skin cancer	0.000169	0.0156	CbGeAlD
Orphenadrine—SLC6A2—head—skin cancer	0.000168	0.0156	CbGeAlD
Orphenadrine—Dizziness—Fluorouracil—skin cancer	0.000164	0.00607	CcSEcCtD
Orphenadrine—GRIN1—Axon guidance—SCN10A—skin cancer	0.000162	0.00858	CbGpPWpGaD
Orphenadrine—Nausea—Temozolomide—skin cancer	0.00016	0.00591	CcSEcCtD
Orphenadrine—SCN9A—Developmental Biology—SCN10A—skin cancer	0.000159	0.00845	CbGpPWpGaD
Orphenadrine—Somnolence—Docetaxel—skin cancer	0.000159	0.00589	CcSEcCtD
Orphenadrine—Vomiting—Fluorouracil—skin cancer	0.000158	0.00583	CcSEcCtD
Orphenadrine—Headache—Fluorouracil—skin cancer	0.000155	0.00575	CcSEcCtD
Orphenadrine—CYP2B6—lymphoid tissue—skin cancer	0.000153	0.0142	CbGeAlD
Orphenadrine—Constipation—Docetaxel—skin cancer	0.000153	0.00566	CcSEcCtD
Orphenadrine—KCNH2—head—skin cancer	0.00015	0.014	CbGeAlD
Orphenadrine—CYP2B6—female reproductive system—skin cancer	0.000148	0.0137	CbGeAlD
Orphenadrine—Feeling abnormal—Docetaxel—skin cancer	0.000148	0.00546	CcSEcCtD
Orphenadrine—Nausea—Fluorouracil—skin cancer	0.000147	0.00545	CcSEcCtD
Orphenadrine—GRIN2D—Post NMDA receptor activation events—HRAS—skin cancer	0.000147	0.00779	CbGpPWpGaD
Orphenadrine—SCN4A—Developmental Biology—SCN10A—skin cancer	0.000146	0.00777	CbGpPWpGaD
Orphenadrine—HRH1—female reproductive system—skin cancer	0.000144	0.0134	CbGeAlD
Orphenadrine—CYP2E1—lymphoid tissue—skin cancer	0.000144	0.0134	CbGeAlD
Orphenadrine—SCN1A—Developmental Biology—SCN10A—skin cancer	0.000141	0.00749	CbGpPWpGaD
Orphenadrine—SCN5A—Axon guidance—SCN10A—skin cancer	0.000139	0.00738	CbGpPWpGaD
Orphenadrine—CYP2E1—female reproductive system—skin cancer	0.000139	0.0129	CbGeAlD
Orphenadrine—GRIN2D—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	0.000135	0.00718	CbGpPWpGaD
Orphenadrine—Hypersensitivity—Docetaxel—skin cancer	0.000132	0.00488	CcSEcCtD
Orphenadrine—Asthenia—Docetaxel—skin cancer	0.000128	0.00475	CcSEcCtD
Orphenadrine—SCN9A—Axon guidance—RASA1—skin cancer	0.000128	0.0068	CbGpPWpGaD
Orphenadrine—GRIN1—CREB phosphorylation through the activation of Ras—HRAS—skin cancer	0.000128	0.00678	CbGpPWpGaD
Orphenadrine—Pruritus—Docetaxel—skin cancer	0.000127	0.00468	CcSEcCtD
Orphenadrine—SLC6A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000124	0.0066	CbGpPWpGaD
Orphenadrine—CYP2B6—head—skin cancer	0.000123	0.0115	CbGeAlD
Orphenadrine—HRH1—head—skin cancer	0.000121	0.0112	CbGeAlD
Orphenadrine—Dizziness—Docetaxel—skin cancer	0.000118	0.00438	CcSEcCtD
Orphenadrine—SCN4A—Axon guidance—RASA1—skin cancer	0.000118	0.00625	CbGpPWpGaD
Orphenadrine—SLC6A2—lymph node—skin cancer	0.000117	0.0109	CbGeAlD
Orphenadrine—CYP2E1—head—skin cancer	0.000116	0.0108	CbGeAlD
Orphenadrine—GRIN1—Developmental Biology—SCN10A—skin cancer	0.000115	0.00613	CbGpPWpGaD
Orphenadrine—Vomiting—Docetaxel—skin cancer	0.000114	0.00421	CcSEcCtD
Orphenadrine—SCN10A—Axon guidance—RASA1—skin cancer	0.000114	0.00603	CbGpPWpGaD
Orphenadrine—SCN1A—Axon guidance—RASA1—skin cancer	0.000114	0.00603	CbGpPWpGaD
Orphenadrine—Headache—Docetaxel—skin cancer	0.000112	0.00415	CcSEcCtD
Orphenadrine—CYP3A4—female reproductive system—skin cancer	0.000112	0.0104	CbGeAlD
Orphenadrine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	0.00011	0.00584	CbGpPWpGaD
Orphenadrine—CHRM2—GPCRs, Other—SMO—skin cancer	0.000108	0.00576	CbGpPWpGaD
Orphenadrine—Nausea—Docetaxel—skin cancer	0.000106	0.00393	CcSEcCtD
Orphenadrine—KCNH2—lymph node—skin cancer	0.000105	0.00978	CbGeAlD
Orphenadrine—GRIN1—Post NMDA receptor activation events—HRAS—skin cancer	0.000105	0.00558	CbGpPWpGaD
Orphenadrine—GRIN1—Spinal Cord Injury—CDK4—skin cancer	0.000102	0.00542	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—SCN10A—skin cancer	9.92e-05	0.00526	CbGpPWpGaD
Orphenadrine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—skin cancer	9.68e-05	0.00514	CbGpPWpGaD
Orphenadrine—GRIN1—EPHB-mediated forward signaling—HRAS—skin cancer	9.68e-05	0.00514	CbGpPWpGaD
Orphenadrine—GRIN1—Axon guidance—RASA1—skin cancer	9.29e-05	0.00493	CbGpPWpGaD
Orphenadrine—SCN9A—Developmental Biology—RASA1—skin cancer	9.14e-05	0.00485	CbGpPWpGaD
Orphenadrine—HRH1—lymph node—skin cancer	8.44e-05	0.00784	CbGeAlD
Orphenadrine—SCN4A—Developmental Biology—RASA1—skin cancer	8.4e-05	0.00446	CbGpPWpGaD
Orphenadrine—GRIN2D—Alzheimers Disease—TP53—skin cancer	8.36e-05	0.00444	CbGpPWpGaD
Orphenadrine—GRIN2D—Transmission across Chemical Synapses—BRAF—skin cancer	8.28e-05	0.00439	CbGpPWpGaD
Orphenadrine—SCN10A—Developmental Biology—RASA1—skin cancer	8.1e-05	0.0043	CbGpPWpGaD
Orphenadrine—SCN1A—Developmental Biology—RASA1—skin cancer	8.1e-05	0.0043	CbGpPWpGaD
Orphenadrine—SCN5A—Axon guidance—RASA1—skin cancer	7.98e-05	0.00424	CbGpPWpGaD
Orphenadrine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—skin cancer	7.88e-05	0.00419	CbGpPWpGaD
Orphenadrine—KCNH2—Hematopoietic Stem Cell Differentiation—IL6—skin cancer	7.87e-05	0.00418	CbGpPWpGaD
Orphenadrine—GRIN1—Spinal Cord Injury—PTGS2—skin cancer	7.3e-05	0.00388	CbGpPWpGaD
Orphenadrine—HRH1—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	7.09e-05	0.00376	CbGpPWpGaD
Orphenadrine—CHRM2—GPCRs, Class A Rhodopsin-like—MC1R—skin cancer	6.98e-05	0.0037	CbGpPWpGaD
Orphenadrine—GRIN1—Developmental Biology—RASA1—skin cancer	6.63e-05	0.00352	CbGpPWpGaD
Orphenadrine—HRH1—GPCR ligand binding—PTCH2—skin cancer	6.4e-05	0.0034	CbGpPWpGaD
Orphenadrine—GRIN2D—Neuronal System—BRAF—skin cancer	6.34e-05	0.00337	CbGpPWpGaD
Orphenadrine—SLC6A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	6.32e-05	0.00336	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR ligand binding—PTCH2—skin cancer	6.29e-05	0.00334	CbGpPWpGaD
Orphenadrine—HRH1—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	6.07e-05	0.00322	CbGpPWpGaD
Orphenadrine—GRIN1—Alzheimers Disease—TP53—skin cancer	5.99e-05	0.00318	CbGpPWpGaD
Orphenadrine—CHRM2—Class A/1 (Rhodopsin-like receptors)—MC1R—skin cancer	5.98e-05	0.00317	CbGpPWpGaD
Orphenadrine—GRIN1—Transmission across Chemical Synapses—BRAF—skin cancer	5.93e-05	0.00315	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—RASA1—skin cancer	5.69e-05	0.00302	CbGpPWpGaD
Orphenadrine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	5.06e-05	0.00269	CbGpPWpGaD
Orphenadrine—GRIN1—EPH-Ephrin signaling—HRAS—skin cancer	4.99e-05	0.00265	CbGpPWpGaD
Orphenadrine—HRH1—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	4.66e-05	0.00247	CbGpPWpGaD
Orphenadrine—HRH1—GPCR ligand binding—MC1R—skin cancer	4.62e-05	0.00246	CbGpPWpGaD
Orphenadrine—CHRM2—GPCRs, Class A Rhodopsin-like—PTGER4—skin cancer	4.59e-05	0.00244	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR ligand binding—MC1R—skin cancer	4.55e-05	0.00242	CbGpPWpGaD
Orphenadrine—GRIN1—Neuronal System—BRAF—skin cancer	4.54e-05	0.00241	CbGpPWpGaD
Orphenadrine—SCN9A—Developmental Biology—CDK4—skin cancer	4.48e-05	0.00238	CbGpPWpGaD
Orphenadrine—GRIN1—Spinal Cord Injury—TP53—skin cancer	4.35e-05	0.00231	CbGpPWpGaD
Orphenadrine—SCN4A—Developmental Biology—CDK4—skin cancer	4.12e-05	0.00219	CbGpPWpGaD
Orphenadrine—HRH1—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	3.99e-05	0.00212	CbGpPWpGaD
Orphenadrine—GRIN1—Spinal Cord Injury—IL6—skin cancer	3.98e-05	0.00211	CbGpPWpGaD
Orphenadrine—SCN1A—Developmental Biology—CDK4—skin cancer	3.97e-05	0.00211	CbGpPWpGaD
Orphenadrine—SCN10A—Developmental Biology—CDK4—skin cancer	3.97e-05	0.00211	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—RHOU—skin cancer	3.97e-05	0.00211	CbGpPWpGaD
Orphenadrine—CHRM2—Class A/1 (Rhodopsin-like receptors)—PTGER4—skin cancer	3.93e-05	0.00209	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—RHOU—skin cancer	3.91e-05	0.00207	CbGpPWpGaD
Orphenadrine—GRIN2D—Transmission across Chemical Synapses—HRAS—skin cancer	3.8e-05	0.00202	CbGpPWpGaD
Orphenadrine—KCNH2—Neuronal System—BRAF—skin cancer	3.78e-05	0.00201	CbGpPWpGaD
Orphenadrine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—skin cancer	3.63e-05	0.00192	CbGpPWpGaD
Orphenadrine—GRIN1—BDNF signaling pathway—HRAS—skin cancer	3.54e-05	0.00188	CbGpPWpGaD
Orphenadrine—SCN9A—Axon guidance—NRAS—skin cancer	3.49e-05	0.00185	CbGpPWpGaD
Orphenadrine—CHRM2—Regulation of Actin Cytoskeleton—BRAF—skin cancer	3.32e-05	0.00177	CbGpPWpGaD
Orphenadrine—HRH1—GPCR ligand binding—SHH—skin cancer	3.3e-05	0.00175	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—PTCH2—skin cancer	3.28e-05	0.00174	CbGpPWpGaD
Orphenadrine—GRIN1—Developmental Biology—CDK4—skin cancer	3.25e-05	0.00173	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR ligand binding—SHH—skin cancer	3.24e-05	0.00172	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—PTCH2—skin cancer	3.23e-05	0.00172	CbGpPWpGaD
Orphenadrine—SCN4A—Axon guidance—NRAS—skin cancer	3.21e-05	0.0017	CbGpPWpGaD
Orphenadrine—GRIN1—SIDS Susceptibility Pathways—IL6—skin cancer	3.18e-05	0.00169	CbGpPWpGaD
Orphenadrine—HRH1—GPCR ligand binding—PTCH1—skin cancer	3.12e-05	0.00166	CbGpPWpGaD
Orphenadrine—HRH1—GPCR ligand binding—SMO—skin cancer	3.12e-05	0.00166	CbGpPWpGaD
Orphenadrine—SCN10A—Axon guidance—NRAS—skin cancer	3.1e-05	0.00164	CbGpPWpGaD
Orphenadrine—SCN1A—Axon guidance—NRAS—skin cancer	3.1e-05	0.00164	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR ligand binding—PTCH1—skin cancer	3.07e-05	0.00163	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR ligand binding—SMO—skin cancer	3.07e-05	0.00163	CbGpPWpGaD
Orphenadrine—HRH1—GPCR ligand binding—PTGER4—skin cancer	3.04e-05	0.00161	CbGpPWpGaD
Orphenadrine—SCN9A—Axon guidance—KRAS—skin cancer	3.01e-05	0.0016	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR ligand binding—PTGER4—skin cancer	2.99e-05	0.00159	CbGpPWpGaD
Orphenadrine—GRIN2D—Neuronal System—HRAS—skin cancer	2.92e-05	0.00155	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—CDK4—skin cancer	2.79e-05	0.00148	CbGpPWpGaD
Orphenadrine—SCN4A—Axon guidance—KRAS—skin cancer	2.76e-05	0.00147	CbGpPWpGaD
Orphenadrine—SCN5A—SIDS Susceptibility Pathways—IL6—skin cancer	2.73e-05	0.00145	CbGpPWpGaD
Orphenadrine—GRIN1—Transmission across Chemical Synapses—HRAS—skin cancer	2.73e-05	0.00145	CbGpPWpGaD
Orphenadrine—SCN10A—Axon guidance—KRAS—skin cancer	2.66e-05	0.00141	CbGpPWpGaD
Orphenadrine—SCN1A—Axon guidance—KRAS—skin cancer	2.66e-05	0.00141	CbGpPWpGaD
Orphenadrine—KCNH2—SIDS Susceptibility Pathways—IL6—skin cancer	2.65e-05	0.00141	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—MC1R—skin cancer	2.61e-05	0.00139	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—MC1R—skin cancer	2.57e-05	0.00137	CbGpPWpGaD
Orphenadrine—SCN9A—Axon guidance—HRAS—skin cancer	2.56e-05	0.00136	CbGpPWpGaD
Orphenadrine—GRIN1—Axon guidance—NRAS—skin cancer	2.53e-05	0.00134	CbGpPWpGaD
Orphenadrine—SCN9A—Developmental Biology—NRAS—skin cancer	2.49e-05	0.00132	CbGpPWpGaD
Orphenadrine—SCN9A—Axon guidance—IL6—skin cancer	2.45e-05	0.0013	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—MC1R—skin cancer	2.37e-05	0.00126	CbGpPWpGaD
Orphenadrine—SCN4A—Axon guidance—HRAS—skin cancer	2.35e-05	0.00125	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—MC1R—skin cancer	2.34e-05	0.00124	CbGpPWpGaD
Orphenadrine—SCN4A—Developmental Biology—NRAS—skin cancer	2.29e-05	0.00122	CbGpPWpGaD
Orphenadrine—SCN10A—Axon guidance—HRAS—skin cancer	2.26e-05	0.0012	CbGpPWpGaD
Orphenadrine—SCN1A—Axon guidance—HRAS—skin cancer	2.26e-05	0.0012	CbGpPWpGaD
Orphenadrine—SCN4A—Axon guidance—IL6—skin cancer	2.25e-05	0.00119	CbGpPWpGaD
Orphenadrine—SCN10A—Developmental Biology—NRAS—skin cancer	2.21e-05	0.00117	CbGpPWpGaD
Orphenadrine—SCN1A—Developmental Biology—NRAS—skin cancer	2.21e-05	0.00117	CbGpPWpGaD
Orphenadrine—GRIN1—Axon guidance—KRAS—skin cancer	2.18e-05	0.00116	CbGpPWpGaD
Orphenadrine—SCN5A—Axon guidance—NRAS—skin cancer	2.18e-05	0.00116	CbGpPWpGaD
Orphenadrine—SCN1A—Axon guidance—IL6—skin cancer	2.17e-05	0.00115	CbGpPWpGaD
Orphenadrine—SCN10A—Axon guidance—IL6—skin cancer	2.17e-05	0.00115	CbGpPWpGaD
Orphenadrine—SCN9A—Developmental Biology—KRAS—skin cancer	2.15e-05	0.00114	CbGpPWpGaD
Orphenadrine—CHRM2—Regulation of Actin Cytoskeleton—NRAS—skin cancer	2.09e-05	0.00111	CbGpPWpGaD
Orphenadrine—GRIN1—Neuronal System—HRAS—skin cancer	2.09e-05	0.00111	CbGpPWpGaD
Orphenadrine—SCN4A—Developmental Biology—KRAS—skin cancer	1.97e-05	0.00105	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PTCH2—skin cancer	1.94e-05	0.00103	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PTCH2—skin cancer	1.91e-05	0.00101	CbGpPWpGaD
Orphenadrine—SCN10A—Developmental Biology—KRAS—skin cancer	1.9e-05	0.00101	CbGpPWpGaD
Orphenadrine—SCN1A—Developmental Biology—KRAS—skin cancer	1.9e-05	0.00101	CbGpPWpGaD
Orphenadrine—SCN5A—Axon guidance—KRAS—skin cancer	1.87e-05	0.000995	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PLIN2—skin cancer	1.86e-05	0.00099	CbGpPWpGaD
Orphenadrine—GRIN1—Axon guidance—HRAS—skin cancer	1.85e-05	0.000984	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PLIN2—skin cancer	1.83e-05	0.000969	CbGpPWpGaD
Orphenadrine—SCN9A—Developmental Biology—HRAS—skin cancer	1.82e-05	0.000968	CbGpPWpGaD
Orphenadrine—GRIN1—Developmental Biology—NRAS—skin cancer	1.81e-05	0.000959	CbGpPWpGaD
Orphenadrine—CHRM2—Regulation of Actin Cytoskeleton—KRAS—skin cancer	1.8e-05	0.000955	CbGpPWpGaD
Orphenadrine—GRIN1—Axon guidance—IL6—skin cancer	1.77e-05	0.000941	CbGpPWpGaD
Orphenadrine—SCN9A—Developmental Biology—IL6—skin cancer	1.75e-05	0.000927	CbGpPWpGaD
Orphenadrine—KCNH2—Neuronal System—HRAS—skin cancer	1.74e-05	0.000923	CbGpPWpGaD
Orphenadrine—HRH1—GPCR downstream signaling—PTGER4—skin cancer	1.72e-05	0.000913	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—SHH—skin cancer	1.69e-05	0.000898	CbGpPWpGaD
Orphenadrine—CHRM2—GPCR downstream signaling—PTGER4—skin cancer	1.69e-05	0.000898	CbGpPWpGaD
Orphenadrine—SCN4A—Developmental Biology—HRAS—skin cancer	1.68e-05	0.00089	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—SHH—skin cancer	1.66e-05	0.000884	CbGpPWpGaD
Orphenadrine—SCN10A—Developmental Biology—HRAS—skin cancer	1.62e-05	0.000858	CbGpPWpGaD
Orphenadrine—SCN1A—Developmental Biology—HRAS—skin cancer	1.62e-05	0.000858	CbGpPWpGaD
Orphenadrine—SCN4A—Developmental Biology—IL6—skin cancer	1.6e-05	0.000852	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—SMO—skin cancer	1.6e-05	0.000851	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—PTCH1—skin cancer	1.6e-05	0.000851	CbGpPWpGaD
Orphenadrine—SCN5A—Axon guidance—HRAS—skin cancer	1.59e-05	0.000845	CbGpPWpGaD
Orphenadrine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.58e-05	0.000841	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—SMO—skin cancer	1.58e-05	0.000838	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—PTCH1—skin cancer	1.58e-05	0.000838	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—PTGER4—skin cancer	1.56e-05	0.000829	CbGpPWpGaD
Orphenadrine—GRIN1—Developmental Biology—KRAS—skin cancer	1.56e-05	0.000826	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—NRAS—skin cancer	1.55e-05	0.000825	CbGpPWpGaD
Orphenadrine—SCN1A—Developmental Biology—IL6—skin cancer	1.55e-05	0.000821	CbGpPWpGaD
Orphenadrine—SCN10A—Developmental Biology—IL6—skin cancer	1.55e-05	0.000821	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—PTGER4—skin cancer	1.54e-05	0.000815	CbGpPWpGaD
Orphenadrine—SCN5A—Axon guidance—IL6—skin cancer	1.52e-05	0.000809	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—CSPG4—skin cancer	1.5e-05	0.000798	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—CSPG4—skin cancer	1.47e-05	0.000781	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—GLI2—skin cancer	1.47e-05	0.00078	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—GLI2—skin cancer	1.45e-05	0.000768	CbGpPWpGaD
Orphenadrine—CHRM2—SIDS Susceptibility Pathways—IL6—skin cancer	1.41e-05	0.000749	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—MC1R—skin cancer	1.4e-05	0.000744	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—GLI1—skin cancer	1.38e-05	0.000734	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—MC1R—skin cancer	1.38e-05	0.000732	CbGpPWpGaD
Orphenadrine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.36e-05	0.000724	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—GLI1—skin cancer	1.36e-05	0.000722	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—KRAS—skin cancer	1.34e-05	0.00071	CbGpPWpGaD
Orphenadrine—GRIN1—Developmental Biology—HRAS—skin cancer	1.32e-05	0.000702	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—SUFU—skin cancer	1.31e-05	0.000696	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—SUFU—skin cancer	1.29e-05	0.000684	CbGpPWpGaD
Orphenadrine—GRIN1—Developmental Biology—IL6—skin cancer	1.27e-05	0.000672	CbGpPWpGaD
Orphenadrine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.16e-05	0.000615	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—HRAS—skin cancer	1.14e-05	0.000603	CbGpPWpGaD
Orphenadrine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.11e-05	0.000589	CbGpPWpGaD
Orphenadrine—SCN5A—Developmental Biology—IL6—skin cancer	1.09e-05	0.000577	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—ENO2—skin cancer	1.02e-05	0.000542	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—ENO2—skin cancer	1e-05	0.000531	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—SHH—skin cancer	9.99e-06	0.00053	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—RASA1—skin cancer	9.93e-06	0.000527	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—SHH—skin cancer	9.83e-06	0.000522	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—RASA1—skin cancer	9.77e-06	0.000519	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PTCH1—skin cancer	9.47e-06	0.000503	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—SMO—skin cancer	9.47e-06	0.000503	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—SMO—skin cancer	9.32e-06	0.000495	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PTCH1—skin cancer	9.32e-06	0.000495	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—PTGER4—skin cancer	9.22e-06	0.00049	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—PTGER4—skin cancer	9.07e-06	0.000482	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PLIN2—skin cancer	8.47e-06	0.00045	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—FOXO4—skin cancer	8.14e-06	0.000432	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—FOXO4—skin cancer	8.01e-06	0.000425	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—CSPG4—skin cancer	6.83e-06	0.000362	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—ERCC2—skin cancer	5.93e-06	0.000315	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—ERCC2—skin cancer	5.81e-06	0.000308	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—TERT—skin cancer	5.44e-06	0.000289	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—TERT—skin cancer	5.35e-06	0.000284	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—ENO2—skin cancer	4.64e-06	0.000246	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—NRAS—skin cancer	4.58e-06	0.000243	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—NRAS—skin cancer	4.51e-06	0.000239	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—BRAF—skin cancer	4.31e-06	0.000229	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—BRAF—skin cancer	4.24e-06	0.000225	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—KRAS—skin cancer	3.94e-06	0.000209	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—KRAS—skin cancer	3.88e-06	0.000206	CbGpPWpGaD
Orphenadrine—CYP2B6—Metabolism—PTGS2—skin cancer	3.56e-06	0.000189	CbGpPWpGaD
Orphenadrine—CYP2E1—Metabolism—PTGS2—skin cancer	3.48e-06	0.000185	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—HRAS—skin cancer	3.35e-06	0.000178	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—HRAS—skin cancer	3.3e-06	0.000175	CbGpPWpGaD
Orphenadrine—HRH1—Signaling by GPCR—IL6—skin cancer	3.21e-06	0.00017	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling by GPCR—IL6—skin cancer	3.16e-06	0.000168	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—NRAS—skin cancer	2.71e-06	0.000144	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—ERCC2—skin cancer	2.7e-06	0.000143	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—NRAS—skin cancer	2.66e-06	0.000141	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—KRAS—skin cancer	2.33e-06	0.000124	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—KRAS—skin cancer	2.29e-06	0.000122	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—TP53—skin cancer	2.07e-06	0.00011	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—TP53—skin cancer	2.04e-06	0.000108	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—HRAS—skin cancer	1.98e-06	0.000105	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—HRAS—skin cancer	1.95e-06	0.000103	CbGpPWpGaD
Orphenadrine—HRH1—Signaling Pathways—IL6—skin cancer	1.9e-06	0.000101	CbGpPWpGaD
Orphenadrine—CHRM2—Signaling Pathways—IL6—skin cancer	1.87e-06	9.9e-05	CbGpPWpGaD
Orphenadrine—CYP3A4—Metabolism—PTGS2—skin cancer	1.62e-06	8.58e-05	CbGpPWpGaD
